EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily A Member 1-Like

Ensembl ID : ENSMAMG00000020598
Gene Symbol: LOC113142087
2 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSMAMG00000008691
Gene Symbol: KCND3
3 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSMAMG00000008331
Gene Symbol: LOC113145621
2 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSMAMG00000009234
Gene Symbol: KCNQ2
2 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSMAMG00000015527
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSMAMG00000022134
Gene Symbol: KCNQ5
3 Cross references
196 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSMAMG00000009627
Gene Symbol: KCND3
3 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2b

Ensembl ID : ENSMAMG00000021819
Gene Symbol: KCNH2B
2 Cross references
185 Possible Orthologues:

Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 3-Like

Ensembl ID : ENSMAMG00000000745
Gene Symbol: LOC113133076
2 Cross references
212 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSMAMG00000000138
Gene Symbol: PSEN1
2 Cross references
200 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSMAMG00000018132
Gene Symbol: PSEN2
2 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSMAMG00000024381
Gene Symbol: PSENEN
3 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).